Form 4: BioXcel Grants 70,000 RSUs to Chief Legal Officer

BioXcel Therapeutics, Inc. granted 70,000 Restricted Stock Units to Chief Legal Officer Javier Rodriguez, vesting over two years.

Summary

• Javier Rodriguez, Chief Legal Officer, Senior Vice President, and Corporate Secretary of BioXcel Therapeutics, Inc. (BTAI), was granted 70,000 Restricted Stock Units (RSUs).
• Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
• The grant date for these RSUs was January 1, 2026.
• The RSUs will vest as to 25% of the underlying shares on the six-month anniversary of the original promise date of November 4, 2025, which is May 4, 2026 (the "Vesting Commencement Date").
• The remaining 75% will vest in three equal installments of 25% on the last day of each subsequent six-month period thereafter.
• The RSUs are fully vested on the two-year anniversary of the Vesting Commencement Date, specifically May 4, 2028, subject to continuous employment.
• Following this transaction, Mr. Rodriguez beneficially owns 70,282 derivative securities (RSUs).

Sentiment

Score: 6

Explanation: The grant of equity to a key executive is generally viewed as a positive for aligning interests, but it is a routine compensation event rather than a significant operational or financial development.

Positives

• The grant of 70,000 Restricted Stock Units (RSUs) to a key executive aligns management's long-term interests with those of shareholders.
• Equity-based compensation incentivizes the Chief Legal Officer to contribute to the company's sustained growth and performance.

Risks

• The vesting of RSUs is contingent upon the reporting person's continuous employment with the Issuer through the relevant vesting dates.

Future Outlook

The vesting schedule for the Restricted Stock Units extends over two years, indicating a long-term commitment for the Chief Legal Officer to remain with the company and contribute to its future performance.

Industry Context

The grant of Restricted Stock Units is a common and widely accepted practice in the biotechnology and pharmaceutical industries for executive compensation, aiming to retain key talent and align their incentives with shareholder value creation.

Comparison to Industry Standards

• Equity grants, such as Restricted Stock Units (RSUs), are a standard component of executive compensation packages across the biotechnology and pharmaceutical sectors, similar to practices observed at companies like Moderna, Pfizer, or Amgen.
• The vesting schedule, typically over several years and contingent on continuous employment, is consistent with industry benchmarks designed to promote long-term executive retention and performance.
• Without specific details on the total compensation package or peer group comparisons, it is difficult to assess the relative size of this RSU grant against industry averages for similar executive roles.

Corporate Governance

Related Party Transactions

• The grant of 70,000 Restricted Stock Units to Javier Rodriguez, a Chief Legal Officer and Senior Vice President, constitutes a related party transaction as it involves an executive officer of the company.

Stakeholder Impact

• Shareholders: The equity grant aims to align the Chief Legal Officer's interests with shareholders, potentially leading to better long-term performance and value creation.
• Employees: The compensation structure for executives can influence overall employee morale and perception of fairness, though this specific grant is for a senior executive.

Next Steps

• Vesting of 25% of the RSUs on May 4, 2026.
• Subsequent vesting of 25% installments every six months thereafter.
• Full vesting of all RSUs by May 4, 2028, subject to continuous employment.

Key Dates

Keywords

BioXcel Therapeutics, BTAI, Restricted Stock Units, RSU, Javier Rodriguez, Executive Compensation, Insider Transaction, Form 4, Equity Grant, Corporate Governance